Home
Search
Search Results
Previously Searched
3083 results found
Expand All
Apply All
3083 results found

Vaccines & Biodefense
Human Health, Biodefense, Vaccines  •  Policy
In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.
Read More

CMS must address Part D plan abuse, says BIO
Good Day BIO Newsletter  •  November 11, 2024
Today, we explore BIO’s recommendations for how CMS can safeguard patient access under Medicare Part D, along with insights on a California Supreme Court case that could affect the complex drug development process, plus more news to know. (748 words, 3 minutes, 44 seconds).As we observe Veterans Day, we honor America’s veterans for their service and sacrifice. Check out our past coverage on how biotech supports veterans and ways to advocate for women veterans.
Read More

BIO Statement on 2024 U.S. Election
Press Release  •  November 6, 2024
WASHINGTON – BIO President & CEO John F. Crowley released the following statement on the results of the 2024 U.S. election:“We look forward to working closely with President-elect Trump, his incoming Administration, and members of Congress on both sides of the aisle to ensure that we have leadership in government that advances the ‘virtuous circle’ of innovation coming from America’s great biotechnology companies.“The public health and our national security are best served by strong leadership that respects and advances science and medicine and ensures that the United States and our allies continue to lead the world in biotechnology.”  About BIOBIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. 
Read More

BIO Files Amicus Brief in California Supreme Court in Continuing Gilead Tenofovir Cases
Intellectual Property, Human Health  •  Amicus Brief  •  November 4, 2024
BIO filed an amicus brief in the Supreme Court of the State of California, encouraging its review of the lower court decision in the Gilead Tenofovir Cases.The Court of Appeal decision operates from a misunderstanding of the drug development and FDA approval processes, particularly failing to see that biopharmaceutical companies cannot reasonably estimate future FDA approval from positive preliminary data from Phase I and II studies, and as such, should not be penalized for making the difficult business decisions to invest in one drug compound over another. This risk of penalization underscores how the Court's decision disincentivizes innovation and biopharma investment.
Read More

Rep. Hank Johnson on biotech, CPAC on PBMs
Good Day BIO Newsletter  •  November 4, 2024
Rep. Hank Johnson discussed the impact of Georgia’s biosciences sector, and CPAC supports FTC action against PBMs. We have details, plus more news on bird flu, USDA biofuel grants, and more. Don’t forget to vote. (678 words, 3 minutes, 23 seconds)
Read More

Open enrollment can be a ‘House of Horrors’
Good Day BIO Newsletter  •  October 31, 2024
Happy Halloween! We explain why open enrollment is scary. (391 words, 1 minutes, 57 seconds)
Read More

Advisory Board
BIO Business Solutions

Patient advocates unite to share stories in D.C.
Good Day BIO Newsletter  •  October 28, 2024
A busy Monday brings all the highlights from BIO's Patient and Health Advocacy Summit last week, plus what BIO's talking about at the World Food Prize event in Iowa tomorrow. (793 words, 3 minutes, 57 seconds)
Read More

Gov't data shows skyrocketing 340B spending
Good Day BIO Newsletter  •  October 25, 2024
A special Friday edition with new data on 340B spending and a New York Times feature highlighting Pivot Bio's outstanding work to support farmers and the planet with biotech. (437 words, 2 minutes, 11 seconds)
Read More

Patient Advocacy
Orphan & Rare Diseases, Patient Advocacy, Rare Diseases  •  Policy
BIO is committed to enhancing patient lives through the discovery, development, and delivery of treatments. To understand the needs of patients, we collaborate closely with patient organizations and caregivers.
Read More